RT Journal Article
T1 Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders.
A1 Wedemeyer, Heiner
A1 Di Marco, Vito
A1 Garcia-Retortillo, Montserrat
A1 Teti, Elisabetta
A1 Fraser, Chris
A1 Morano Amado, Luis Enrique
A1 Rodriguez-Tajes, Sergio
A1 Acosta-López, Silvia
A1 O'Loan, Joss
A1 Milella, Michele
A1 Buti, Maria
A1 Guerra-Veloz, María Fernanda
A1 Ramji, Alnoor
A1 Fenech, Mary
A1 Martins, Alexandra
A1 Borgia, Sergio M
A1 Vanstraelen, Kim
A1 Mertens, Michael
A1 Hernández, Cándido
A1 Ntalla, Ioanna
A1 Ramroth, Heribert
A1 Milligan, Scott
K1 HCV
K1 HCV elimination
K1 mental health disorders
K1 real-world
K1 sofosbuvir/velpatasvir
AB Hepatitis C virus (HCV) is prevalent in people with mental health disorders, a priority population to diagnose and cure in order to achieve HCV elimination. This integrated analysis pooled data from 20 cohorts in seven countries to evaluate the real-world effectiveness of the pangenotypic direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) in people with mental health disorders. HCV-infected patients diagnosed with mental health disorders who were treated with SOF/VEL for 12 weeks without ribavirin as part of routine clinical practice were included. The primary outcome was sustained virological response (SVR) in the effectiveness population (EP), defined as patients with an available SVR assessment. Secondary outcomes were reasons for not achieving SVR, characteristics of patients with non-virological failures, adherence, and time from HCV RNA diagnosis to SOF/VEL treatment initiation. A total of 1209 patients were included; 142 did not achieve an SVR for non-virological reasons (n = 112; 83 lost to follow-up, 20 early treatment discontinuations) or unknown reasons (n = 30). Of the 1067 patients in the EP, 97.4% achieved SVR. SVR rates in the EP were ≥95% when stratified by type of mental health disorder and other complicating baseline characteristics, including active injection drug use and antipsychotic drug use. Of 461 patients with data available in the EP, only 2% had an adherence level
YR 2022
FD 2022-11-11
LK http://hdl.handle.net/10668/21603
UL http://hdl.handle.net/10668/21603
LA en
DS RISalud
RD Apr 8, 2025